$542.85 Million in Sales Expected for Masimo Co. (NASDAQ:MASI) This Quarter

Wall Street analysts expect Masimo Co. (NASDAQ:MASIGet Rating) to post $542.85 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Masimo’s earnings. The highest sales estimate is $543.28 million and the lowest is $542.41 million. Masimo posted sales of $305.12 million during the same quarter last year, which suggests a positive year over year growth rate of 77.9%. The company is expected to announce its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Masimo will report full year sales of $1.81 billion for the current financial year, with estimates ranging from $1.35 billion to $2.04 billion. For the next financial year, analysts forecast that the firm will report sales of $2.18 billion, with estimates ranging from $1.52 billion to $2.55 billion. Zacks’ sales calculations are an average based on a survey of sell-side analysts that follow Masimo.

Masimo (NASDAQ:MASIGet Rating) last posted its quarterly earnings data on Tuesday, May 3rd. The medical equipment provider reported $0.93 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.01. The company had revenue of $304.24 million during the quarter, compared to analysts’ expectations of $308.04 million. Masimo had a return on equity of 15.46% and a net margin of 17.91%. Masimo’s revenue for the quarter was up 1.7% compared to the same quarter last year. During the same period in the prior year, the business earned $0.90 earnings per share.

MASI has been the topic of several research reports. TheStreet cut Masimo from a “b-” rating to a “c+” rating in a research note on Tuesday, February 22nd. Needham & Company LLC decreased their price target on Masimo from $205.00 to $163.00 in a research note on Wednesday, May 4th. UBS Group decreased their target price on Masimo from $325.00 to $295.00 and set a “buy” rating for the company in a research note on Wednesday, February 16th. Wolfe Research assumed coverage on Masimo in a report on Tuesday, April 5th. They issued a “market perform” rating and a $160.00 target price on the stock. Finally, Stifel Nicolaus dropped their price target on Masimo from $175.00 to $150.00 in a report on Wednesday, May 4th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Masimo currently has a consensus rating of “Buy” and an average target price of $199.33.

A number of large investors have recently added to or reduced their stakes in MASI. Two Sigma Advisers LP grew its position in shares of Masimo by 201.5% in the third quarter. Two Sigma Advisers LP now owns 60,600 shares of the medical equipment provider’s stock valued at $16,405,000 after purchasing an additional 40,500 shares in the last quarter. Robeco Institutional Asset Management B.V. grew its position in Masimo by 73.8% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 4,619 shares of the medical equipment provider’s stock worth $1,353,000 after buying an additional 1,961 shares in the last quarter. Itau Unibanco Holding S.A. purchased a new position in Masimo during the fourth quarter worth about $80,000. Astrantus Ltd purchased a new position in Masimo during the fourth quarter worth about $339,000. Finally, LPL Financial LLC grew its position in Masimo by 8.0% during the third quarter. LPL Financial LLC now owns 29,006 shares of the medical equipment provider’s stock worth $7,852,000 after buying an additional 2,152 shares in the last quarter. 92.03% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ:MASI opened at $140.00 on Friday. Masimo has a twelve month low of $112.07 and a twelve month high of $305.21. The firm has a market cap of $7.77 billion, a PE ratio of 36.18 and a beta of 0.98. The business has a fifty day moving average of $135.81 and a 200-day moving average of $194.23.

Masimo Company Profile (Get Rating)

Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Further Reading

Get a free copy of the Zacks research report on Masimo (MASI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.